Esperion Therapeutics Reports Strong Q3 Revenue Growth

Esperion Therapeutics ( (ESPR) ) has released its Q3 earnings. Here is a breakdown of the information Esperion Therapeutics presented to its investors.

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing non-statin medicines for cardiovascular disease, with a unique emphasis on patients with elevated LDL-C levels who are statin intolerant.

In its third-quarter 2025 financial report, Esperion Therapeutics announced a significant 69% year-over-year increase in total revenue, reaching $87.3 million. The company also highlighted strategic achievements, including a settlement agreement with Dr. Reddy’s Laboratories to delay generic competition for its key products until 2040 and the inclusion of its drug bempedoic acid in the updated European guidelines for dyslipidemia management.

Key financial metrics from the report reveal a 31% year-over-year growth in U.S. net product revenue to $40.7 million and a 128% increase in collaboration revenue for the quarter. Despite these gains, the company reported a net loss of $31.3 million for the quarter, attributed to increased operating expenses and interest expenses. Esperion also achieved significant milestones in global expansion, with regulatory approvals in Japan and new market entries in Europe.

Esperion’s strategic focus on expanding its market presence and enhancing patient access is evident in its marketing campaigns and partnerships. The company is poised to leverage the anticipated inclusion of bempedoic acid in U.S. guidelines in 2026, aiming to drive further revenue growth and solidify its market position.

Looking ahead, Esperion remains optimistic about achieving sustainable profitability by the first quarter of 2026, driven by its robust commercial strategies, international partnerships, and ongoing investments in clinical development and market expansion.